>

List – 51 Drug Patents that are Expiring in 2023

In 2020, we published an article covering 91 drug patents expiring between 2020-2022. 2022 is already here and if you are working in the pharma domain, working on the development of generics, you would want to know what drug patents are expiring in the coming years, so you could plan accordingly. 

With the explosive growth in the generic drug market, generic companies (like yours) are in a battle to claim a share of the soon-to-be-expired drugs as quickly as possible. You would want to know as much as possible, and keeping that very thought in mind, we collated a list of 51 drugs that are going off-patent 2023. We also included other information like yearly sales, dosage information, ingredients, and the diseases they cure. This could help you easily choose the drug most profitable to develop a generic version. 

Loved the idea and the list? Thank us later in the comments section. Now onto the list.

The article has a list of drug patents expiring in 2023. If you want to get the drug patents expiration list from 2021 to 2025, Download the PDF by filling out the form below.


Patents Expiring in 2023

Entresto
Sacubitril; Valsartan

Sales:
$1.7 Billion (2018)

More information about this Drug

Patents Expiration Date
US7468390 November 27, 2023
US8101659 July 14, 2023
US8404744 July 14, 2023
US8796331 July 14, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corporation
Ingredients: Sacubitril; Valsartan
Treatment: Chronic Heart Failure

Spinraja
Nusinersen Sodium

Sales:
$1.724 Billion (2018)

More information about this Drug

Patents Expiration Date
US7101993 September 05, 2023
US8110560 December 05, 2025
US7838657 July 11, 2027
US8361977 May 27, 2030

Dosage: Solution; Intrathecal
Company: Biogen Idec Inc
Ingredients: Nusinersen Sodium
Treatment: Spinal Muscular Atrophy

Tegsedi
Inotersen Sodium

Sales:
$2.2 Million (Q4, 2018)

More information about this Drug

Patents Expiration Date
US7015315 March 21, 2023
US7101993 September 05, 2023

Dosage: Solution; Subcutaneous
Company: Akcea Therapeutics Inc
Ingredients: Inotersen Sodium
Treatment: Polyneuropathy

Dalvance
Dalbavancin Hydrochloride

Sales:
$81.9 Million (2019)

More information about this Drug

Patents Expiration Date
US6900175 December 25, 2023
US7115564 November 14, 2023
US7119061 November 14, 2023
US8143212 November 14, 2023

Dosage: Powder; Intravenous
Company: Allergan Sales LLC
Ingredients: Dalbavancin Hydrochloride
Treatment: To Treat Severe Skin Infections

Zykadia
Ceritinib

Sales:
$91 Million (2016)

More information about this Drug

Patents Expiration Date
US9416112 January 31, 2023
US8188276 January 31, 2023
US9018204 January 31, 2023
US8835430 January 31, 2023
US7893074 April 25, 2026
US9018204 November 20, 2027
US7964592 April 29, 2028
US8039479 June 29, 2030
US9309229 January 18, 2032

Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Ceritinib
Treatment: Lung Cancer

Promacta
Eltrombopag Olamine

Sales:
$330 Million (Q4, 2018)

More information about this Drug

Patents Expiration Date
US7160870 May 20, 2023
US7547719 January 13, 2026

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Eltrombopag Olamine
Treatment: Thrombocytopenia

Rubraca
Rucaparib Camsylate

Sales:
$142 – $143 Million (2019)

More information about this Drug

Patents Expiration Date
US6495541 November 22, 2023
US9045487 February 10, 2031
US8754072 February 10, 2031

Dosage: Tablet; Oral
Company: Clovis Oncology Inc
Ingredients: Rucaparib Camsylate
Treatment: BRCA-Mutated Ovarian Cancer

Mektovi
Binimetinib

Sales:
$35.1 Million (Q3, 2019)

More information about this Drug

Patents Expiration Date
US7777050 March 13, 2023
US8178693 March 13, 2023
US8193229 March 13, 2023
US8513293 March 13, 2023
US9562016 October 18, 2033

Dosage: Tablet; Oral
Company: Array Biopharma Inc
Ingredients: Binimetinib
Treatment: Unresectable or Metastatic Melanoma with a BRAF V600 Mutation

Zosyn
Piperacillin Sodium, Tazobactam Sodium

Sales:
$51 Million (2019)

More information about this Drug

Patents Expiration Date
US6900184 April 14, 2023
US7915229 April 14, 2023
US8133883 April 14, 2023

Dosage: Injectable; Injection
Company: Wyeth Pharmaceuticals LLC
Ingredients: Piperacillin Sodium; Tazobactum Sodium
Treatment: Bacterial Infections

Boniva
Ibandronate Sodium

Sales:
$517 Million (2011)

More information about this Drug

Patents Expiration Date
US7192938 May 06, 2023
US7410957 May 06, 2023
US7718634 May 06, 2023

Dosage: Injectable; Injection
Company: Hoffmann La Roche Inc
Ingredients: Ibandronate Sodium
Treatment: Osteoporosis

Votrient
Pazopanib Hydrochloride

Sales:
$828 Million (2018)

More information about this Drug

Patents Expiration Date
US7105530 October 19, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Pazopanib Hydrochloride
Treatment: Soft Tissue Sarcomas and Advanced Renal Cell Carcinoma

Tyzeka
Telbivudine

Sales:

More information about this Drug

Patents Expiration Date
US7858594 September 11, 2023
US7589079 September 11, 2023

Dosage: Solution; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Telbivudine
Treatment: Chronic Hepatitis B

Exforge
Amlodipine Besylate; Hydrochlorothiazide; Valsartan

Sales:
$1.025 Billion (2019)

More information about this Drug

Patents Expiration Date
US8101599 May 16, 2023
US8475839 May 16, 2023

Dosage: Tablet; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Amlodipine Besylate; Hydrochlorothiazide; Valsartan
Treatment: High Blood Pressure (Hypertension)

Ozurdex
Dexamethasone

Sales:
$33.7 Million (Q3, 2019)

More information about this Drug

Patents Expiration Date
US8034366 January 09, 2023
US8034370 January 09, 2023
US9192511 January 09, 2023
US10076526 January 09, 2023
US6899717 November 01, 2023
US8506987 January 09, 2023
US10702539 January 09, 2023

Dosage: Implant; Intravitreal
Company: Allergan Inc
Ingredients: Dexamethasone
Treatment: Macular Edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO)

Feraheme
Ferumoxytol

Sales:
$41.7 Million (Q4, 2019)

More information about this Drug

Patents Expiration Date
US6599498 June 30, 2023

Dosage: Solution; Intravenous
Company: Amag Pharmaceuticals Inc
Ingredients: Ferumoxytol
Treatment: Iron Deficiency Anemia

Patanase
Olopatadine Hydrochloride

Sales:

More information about this Drug

Patents Expiration Date
US7977376 February 02, 2023
US8399508 September 17, 2022

Dosage: Spray, Metered; Nasal
Company: Novartis Pharmaceuticals Corp
Ingredients: Olopatadine Hydrochloride
Treatment: Congestion, Sneezing, and Runny Nose caused by Seasonal Allergies

Mozobil
Plerixafor

Sales:
$108.3 Million (2018)

More information about this Drug

Patents Expiration Date
US6987102 July 22, 2023
US7897590 July 22, 2023

Dosage: Solution; Subcutaneous
Company: Genzyme Corp
Ingredients: Plerixafor
Treatment: Non-Hodgkin’s Lymphoma or Multiple Myeloma

Section

Oraverse
Phentolamine Mesylate

Sales:

More information about this Drug

Patents Expiration Date
US7229630 June 20, 2023
US7569230 October 17, 2023

Dosage: Injectable; Injection
Company: Septodont Holding SAS
Ingredients: Phentolamine Mesylate
Treatment: Used for Reversal of the Soft-Tissue Anesthesia

Ryzolt
Tramadol Hydrochloride

Sales:

More information about this Drug

Patents Expiration Date
US7988998 October 27, 2023

Dosage: Tablet, Extended Release; Oral
Company: Purdue Pharma Products LP
Ingredients: Tramadol Hydrochloride
Treatment: Severe Pain

Toviaz
Fesoterodine

Sales:
$69 Million (2020)

More information about this Drug

Patents Expiration Date
US6858650 January 3, 2023

Dosage: Oral
Company: Pfizer
Ingredients: FESOTERODINE FUMARATE
Treatment: Overactive Bladder Syndrome (OAB)

Ibrance
Palbociclib

Sales:
$1.43 Billion (2020)

More information about this Drug

Patents Expiration Date
US6936612 January 16, 2023
US7208489 January 16, 2023
USRE47739 March 5, 2027
US10723730 February 8, 2034

Dosage: Oral
Company: Pfizer
Ingredients: PALBOCICLIB
Treatment: HR-positive and HER2-negative breast cancer

Vizamyl
Flutemetamol

Sales:

More information about this Drug

Patents Expiration Date
US7351401 January 24, 2023
US8236282 May 21, 2024
US7270800 September 3, 2025

Dosage: Intravenous
Company: GE Healthcare
Ingredients: FLUTEMETAMOL F-18
Treatment: Used as a Diagnostic Tool for Alzheimer’s disease

Janumet
Sitagliptin/Metformin

Sales:
$5.2 Billion (2020)

More information about this Drug

Patents Expiration Date
US6699871 January 26, 2023
US7326708 May 24, 2027

Dosage: Oral
Company: Merck & Co
Ingredients: METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Treatment: Type 2 Diabetes

Cipralex/Lexapro
Escitalopram

Sales:
DKK 1.83 Billion (2021)

More information about this Drug

Patents Expiration Date
US6916941 February 12, 2023

Dosage: Oral
Company: Lundbeck
Ingredients: ESCITALOPRAM OXALATE
Treatment: Major Depressive Disorder or Generalized Anxiety Disorder

Victoza
Liraglutide

Sales:
DKK 15.05 Billion (2021)

More information about this Drug

Patents Expiration Date
US6268343 February 22, 2023
US8114833 February 13, 2026

Dosage: Subcutaneous
Company: Novo Nordisk
Ingredients: LIRAGLUTIDE RECOMBINANT
Treatment: Type 2 Diabetes, Obesity, and Chronic Weight Management

Fosamax
Alendronic Acid

Sales:

More information about this Drug

Patents Expiration Date
US7964212 March 6, 2023
US7488496 August 11, 2023

Dosage: Oral
Company: Merck & Co Inc
Ingredients: ALENDRONATE SODIUM
Treatment: Osteoporosis and Paget’s Disease of Bone

Koselugo
Selumetinib

Sales:
$108 Million (2021)

More information about this Drug

Patents Expiration Date
US8178693 March 13, 2023
US7425637 April 11, 2024
US9562017 December 12, 2026
US9156795 December 12, 2026

Dosage: Oral
Company: AstraZeneca
Ingredients: SELUMETINIB SULFATE
Treatment: Neurofibromatosis type I (NF-1)

Akynzeo
Netupitant / Palonosetron

Sales:

More information about this Drug

Patents Expiration Date
US6297375 March 17, 2023
US10233154 September 25, 2035
US9951016 September 25, 2035
US10961195 September 25, 2035
US10676440 September 25, 2035

Dosage: Oral, Intravenous
Company: Helsinn Therapeutics
Ingredients: NETUPITANT; PALONOSETRON HYDROCHLORIDE
Treatment: Acute and Delayed Chemotherapy-induced Nausea and Vomiting

Kynamro
Mipomersen

Sales:

More information about this Drug

Patents Expiration Date
US7015315 March 21, 2023
US7511131 January 29, 2027

Dosage: Subcutaneous Injection
Company: Genzyme Corporation
Ingredients: MIPOMERSEN SODIUM
Treatment: Homozygous Familial Hypercholesterolemia

Incruse Ellipta
Umeclidinium bromide

Sales:

More information about this Drug

Patents Expiration Date
USRE44874 March 23, 2023
US7498440 April 27, 2025
US7439393 May 21, 2025
US7488827 December 18, 2027

Dosage: Inhalation
Company: GlaxoSmithKline
Ingredients: UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
Treatment: Chronic Obstructive Pulmonary Disease (COPD)

Xeljanz
Tofacitinib

Sales:
$696 Milllion (2020)

More information about this Drug

Patents Expiration Date
US6965027 March 25, 2023
USRE41783 December 8, 2025

Dosage: Oral
Company: Pfizer
Ingredients: TOFACITINIB CITRATE
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ulcerative Colitis

Vocabria
Cabotegravir

Sales:

More information about this Drug

Patents Expiration Date
US8080551 April 11, 2023
US7125879 April 21, 2025

Dosage: Oral, Intramuscular
Company: ViiV Healthcare
Ingredients: CABOTEGRAVIR; RILPIVIRINE
Treatment: HIV/AIDS

Dexilant
Dexlansoprazole

Sales:

More information about this Drug

Patents Expiration Date
US6664276 July 30, 2023

Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease

Dutrebis
Lamivudine/raltegravir

Sales:

More information about this Drug

Patents Expiration Date
US7820660 April 25, 2023

Dosage: Oral
Company: Merck Sharp & Dohme Corp.
Ingredients: LAMIVUDINE; RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS

Fotivda
Tivozanib

Sales:
$38.9 Million (2021)

More information about this Drug

Patents Expiration Date
US6821987 April 26, 2023
US7166722 November 16, 2023

Dosage: Oral
Company: AVEO Pharmaceuticals
Ingredients: TIVOZANIB HYDROCHLORIDE
Treatment: Relapsed or Refractory Advanced Renal Cell Carcinoma (RCC)

Banzel
Rufinamide

Sales:

More information about this Drug

Patents Expiration Date
US6740669 May 14, 2023

Dosage: Oral
Company: Eisai Inc.
Ingredients: RUFINAMIDE
Treatment: Seizures Associated with Lennox-Gastaut syndrome

Nuzyra
Omadacycline

Sales:
$38.8 million (2020)

More information about this Drug

Patents Expiration Date
US7553828 June 2, 2023
US7326696 September 24, 2023
US8383610 September 23, 2030

Dosage: Oral, Intravenous
Company: Paratek Pharmaceuticals
Ingredients: OMADACYCLINE TOSYLATE
Treatment: Community-acquired Bacterial Pneumonia and Acute Skin and skin structure infections

Halaven
Eribulin

Sales:

More information about this Drug

Patents Expiration Date
US6214865 July 20, 2023

Dosage: Intravenous
Company: Eisai Inc.
Ingredients: ERIBULIN MESYLATE
Treatment: Breast Cancer and Liposarcoma

Dexilant
Dexlansoprazole

Sales:

More information about this Drug

Patents Expiration Date
US6664276 July 30, 2023

Dosage: Oral
Company: Takeda
Ingredients: DEXLANSOPRAZOLE
Treatment: Gastroesophageal Reflux Disease

Onglyza
Saxagliptin

Sales:
$360 Million (2021)

More information about this Drug

Patents Expiration Date
USRE44186 July 31, 2023

Dosage: Oral
Company: AstraZeneca
Ingredients: METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Vyvanse
Lisdexamfetamine

Sales:
271.5 Billion JPY

More information about this Drug

Patents Expiration Date
US7659253 August 24, 2023
US7655630 August 24, 2023
US7662787 August 24, 2023

Dosage: Oral
Company: Shire (Takeda)
Ingredients: LISDEXAMFETAMINE DIMESYLATE
Treatment: Attention Deficit Hyperactivity Disorder (ADHD)

Lumigan
Bimatoprost

Sales:
$149 Million (2021)

More information about this Drug

Patents Expiration Date
US8038988 August 25, 2023
US7851504 June 13, 2027
US8629185 July 15, 2031

Dosage: Eye Drops
Company: Allergan
Ingredients: BIMATOPROST
Treatment: High Pressure Inside the eye including Glaucoma

Vibativ
Telavancin

Sales:
$11.7 million (2021)

More information about this Drug

Patents Expiration Date
US6635618 September 11, 2023
US7531623 January 1, 2027

Dosage: Intravenous
Company: Theravance Biopharma
Ingredients: TELAVANCIN HYDROCHLORIDE
Treatment: MRSA or other Gram-positive infections

Lupron
Leuprorelin

Sales:
$783 Million (2021)

More information about this Drug

Patents Expiration Date
US8470359 October 15, 2023

Dosage: Subcutaneous, Intramuscular
Company: AbbVie Inc
Ingredients: LEUPROLIDE ACETATE
Treatment: Prostate Cancer, Breast Cancer, Endometriosis, Uterine Fibroids

Feraheme
Ferric Carboxymaltose

Sales:
$167.9 million (2020)

More information about this Drug

Patents Expiration Date
US11123321 October 20, 2023
US9376505 October 20, 2023
US7612109 February 5, 2024

Dosage: Intravenous
Company: AMAG Pharmaceuticals
Ingredients: FERRIC CARBOXYMALTOSE
Treatment: Iron-deficiency Anemia

Ozanex
Ozenoxacin

Sales:

More information about this Drug

Patents Expiration Date
US6335447 November 9, 2023

Dosage: Topical
Company: Cipher Pharmaceuticals
Ingredients: OZENOXACIN
Treatment: Impetigo

Stiolto® Respimat
Tiotropium/olodaterol

Sales:

More information about this Drug

Patents Expiration Date
US7491719 November 10, 2023
US7056916 December 7, 2023
US7220742 May 12, 2025
US7727984 January 19, 2027

Dosage: Inhalation
Company: Boehringer Ingelheim Pharmaceuticals
Ingredients: OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE
Treatment: Asthma

Otezla
Apremilast

Sales:
$2.2 billion (2020)

More information about this Drug

Patents Expiration Date
US7893101 December 9, 2023
US7427638 February 16, 2028

Dosage: Oral
Company: Amgen Inc
Ingredients: APREMILAST
Treatment: Psoriasis and Psoriatic Arthritis

Rapivab
Peramivir

Sales:
$13.9 million (2020)

More information about this Drug

Patents Expiration Date
US6562861 December 16, 2023

Dosage: Intravenous
Company: BioCryst Pharmaceuticals
Ingredients: PERAMIVIR
Treatment: Influenza

VYNDAQEL
Tafamidis/Meglumine

Sales:
$429 Million (2020)

More information about this Drug

Patents Expiration Date
US8168663 December 19, 2023
US7214695 April 27, 2024
US9770441 August 31, 2035

Dosage: Oral
Company: Pfizer
Ingredients: TAFAMIDIS MEGLUMINE
Treatment: Transthyretin Amyloidosis

Coreg
Carvedilol

Sales:

More information about this Drug

Patents Expiration Date
US7268156 December 27, 2023

Dosage: Oral
Company: GlaxoSmithKline
Ingredients: CARVEDILOL PHOSPHATE
Treatment: High Blood Pressure, Congestive Heart Failure (CHF), and Left Ventricular Dysfunction

Conclusion

As a drug patent expires it expands the gateway for a number of competitors to enter the market. Tracking these patent expirations beforehand can not only help evaluate business opportunities but also help in refining market entry strategies. But there still lies legal as well as technology threats and hurdles that a generic company will face depending on the drug they choose for the generic version. 

With proper research and threat analysis, developing a generic version wouldn’t be as terrifying. How to go about it? Well, let’s start with getting in touch by filling the form below and we’ll get back to you in no time.


Authored by: Divya Goyal, Team Lead, Life Science Team, and Madan Ekhande, Research Analyst, Life Science Team

Leave a Comment